{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:47:04Z","timestamp":1793839624817,"version":"4.6.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Guangzhou Science and Technology Plan Project","award":["201902010003"],"award-info":[{"award-number":["201902010003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-49053-6","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T12:06:37Z","timestamp":1777032397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["USP7-dependent stabilization of FKBP4 contributes to acquired osimertinib resistance through glycolytic remodeling in NSCLC"],"prefix":"10.1038","volume":"16","author":[{"given":"Wenguang","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxing","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"issue":"3","key":"49053_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71 (3), 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"49053_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","volume":"41","author":"BC Bade","year":"2020","unstructured":"Bade, B. C. & Dela Cruz, C. S. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin. Chest Med. 41 (1), 1\u201324 (2020).","journal-title":"Clin. Chest Med."},{"issue":"9","key":"49053_CR3","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti, A. et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br. J. Cancer. 121 (9), 725\u2013737 (2019).","journal-title":"Br. J. Cancer"},{"key":"49053_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030841","author":"G Gomatou","year":"2023","unstructured":"Gomatou, G., Syrigos, N. & Kotteas, E. Osimertinib resistance: Molecular mechanisms and emerging treatment options.. Cancers (Basel) 15(3), 841 https:\/\/doi.org\/10.3390\/cancers15030841 (2023).","journal-title":"Cancers (Basel)"},{"issue":"6","key":"49053_CR5","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"KS Thress","year":"2015","unstructured":"Thress, K. S. et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21 (6), 560\u2013562 (2015).","journal-title":"Nat. Med."},{"issue":"1","key":"49053_CR6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41467-018-08074-0","volume":"10","author":"H Taniguchi","year":"2019","unstructured":"Taniguchi, H. et al. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nat. Commun. 10 (1), 259 (2019).","journal-title":"Nat. Commun."},{"issue":"16","key":"49053_CR7","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1158\/0008-5472.CAN-18-0117","volume":"78","author":"JH Kim","year":"2018","unstructured":"Kim, J. H. et al. Enhanced Glycolysis Supports Cell Survival in EGFR-Mutant Lung Adenocarcinoma by Inhibiting Autophagy-Mediated EGFR Degradation. Cancer Res. 78 (16), 4482\u20134496 (2018).","journal-title":"Cancer Res."},{"issue":"1","key":"49053_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41392-024-01928-8","volume":"9","author":"T Zhang","year":"2024","unstructured":"Zhang, T. et al. Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation. Signal. Transduct. Target. Ther. 9 (1), 216 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"2","key":"49053_CR9","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1021\/pr2008187","volume":"11","author":"WS Yang","year":"2012","unstructured":"Yang, W. S. et al. Proteomic approach reveals FKBP4 and S100A9 as potential prediction markers of therapeutic response to neoadjuvant chemotherapy in patients with breast cancer. J. Proteome Res. 11 (2), 1078\u20131088 (2012).","journal-title":"J. Proteome Res."},{"issue":"23","key":"49053_CR10","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.7150\/thno.35561","volume":"9","author":"A Mang\u00e9","year":"2019","unstructured":"Mang\u00e9, A. et al. FKBP4 connects mTORC2 and PI3K to activate the PDK1\/Akt-dependent cell proliferation signaling in breast cancer. Theranostics 9 (23), 7003\u20137015 (2019).","journal-title":"Theranostics"},{"issue":"4","key":"49053_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/1878-0261.12028","volume":"11","author":"JB Joshi","year":"2017","unstructured":"Joshi, J. B. et al. Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52. Mol. Oncol. 11 (4), 337\u2013357 (2017).","journal-title":"Mol. Oncol."},{"issue":"19","key":"49053_CR12","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1111\/j.1742-4658.2010.07795.x","volume":"277","author":"Y Liu","year":"2010","unstructured":"Liu, Y. et al. Proteomic mining in the dysplastic liver of WHV\/c-myc mice\u2013insights and indicators for early hepatocarcinogenesis. Febs j. 277 (19), 4039\u20134053 (2010).","journal-title":"Febs j."},{"issue":"6","key":"49053_CR13","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41419-021-03857-8","volume":"12","author":"S Zong","year":"2021","unstructured":"Zong, S. et al. FKBP4 integrates FKBP4\/Hsp90\/IKK with FKBP4\/Hsp70\/RelA complex to promote lung adenocarcinoma progression via IKK\/NF-\u03baB signaling. Cell Death Dis. 12(6), 602 (2021).","journal-title":"Cell Death Dis."},{"issue":"148","key":"49053_CR14","first-page":"167","volume":"27","author":"S Jonna","year":"2019","unstructured":"Jonna, S. & Subramaniam, D. S. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update. Discov. Med. 27 (148), 167\u2013170 (2019).","journal-title":"Discov. Med."},{"issue":"8","key":"49053_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrc3775","volume":"14","author":"Z Chen","year":"2014","unstructured":"Chen, Z. et al. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat. Rev. Cancer. 14 (8), 535\u2013546 (2014).","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"49053_CR16","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"M Wang","year":"2021","unstructured":"Wang, M., Herbst, R. S. & Boshoff, C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat. Med. 27 (8), 1345\u20131356 (2021).","journal-title":"Nat. Med."},{"key":"49053_CR17","doi-asserted-by":"publisher","first-page":"104108","DOI":"10.1016\/j.critrevonc.2023.104108","volume":"190","author":"C Catania","year":"2023","unstructured":"Catania, C. et al. New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists - INTERACTION group. Crit. Rev. Oncol. Hematol. 190, 104108 (2023).","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"8","key":"49053_CR18","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14737140.2024.2362889","volume":"24","author":"T Landre","year":"2024","unstructured":"Landre, T. et al. First-line concomitant EGFR-TKI\u2009+\u2009chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials. Expert Rev. Anticancer Ther. 24 (8), 775\u2013780 (2024).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"49053_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-pathol-011110-130206","volume":"6","author":"G da Cunha Santos","year":"2011","unstructured":"da Cunha Santos, G., Shepherd, F. A. & Tsao, M. S. EGFR mutations and lung cancer. Annu. Rev. Pathol. 6, 49\u201369 (2011).","journal-title":"Annu. Rev. Pathol."},{"issue":"10454","key":"49053_CR20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","volume":"404","author":"ML Meyer","year":"2024","unstructured":"Meyer, M. L. et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet (London England). 404 (10454), 803\u2013822 (2024).","journal-title":"Lancet (London England)"},{"issue":"2","key":"49053_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","volume":"16","author":"X Le","year":"2021","unstructured":"Le, X. et al. Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. J. Thorac. Oncology: Official Publication Int. Association Study Lung Cancer. 16 (2), 205\u2013215 (2021).","journal-title":"J. Thorac. Oncology: Official Publication Int. Association Study Lung Cancer"},{"key":"49053_CR22","doi-asserted-by":"publisher","first-page":"103194","DOI":"10.1016\/j.critrevonc.2020.103194","volume":"157","author":"EN Imyanitov","year":"2021","unstructured":"Imyanitov, E. N., Iyevleva, A. G. & Levchenko, E. V. Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives. Crit. Rev. Oncol. Hematol. 157, 103194 (2021).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"49053_CR23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.critrevonc.2017.07.003","volume":"117","author":"A Russo","year":"2017","unstructured":"Russo, A. et al. Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going. Crit. Rev. Oncol. Hematol. 117, 38\u201347 (2017).","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"49053_CR24","doi-asserted-by":"publisher","first-page":"26893","DOI":"10.1038\/s41598-024-78383-6","volume":"14","author":"Z Zeng","year":"2024","unstructured":"Zeng, Z. et al. FKBP4 promotes glycolysis and hepatocellular carcinoma progression via p53\/HK2 axis. Sci. Rep. 14 (1), 26893 (2024).","journal-title":"Sci. Rep."},{"issue":"7","key":"49053_CR25","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.7150\/jca.40982","volume":"11","author":"H Xiong","year":"2020","unstructured":"Xiong, H. et al. FKBP4 is a malignant indicator in luminal A subtype of breast cancer. J. Cancer. 11 (7), 1727\u20131736 (2020).","journal-title":"J. Cancer"},{"issue":"12","key":"49053_CR26","first-page":"5339","volume":"15","author":"H Wang","year":"2023","unstructured":"Wang, H., Han, G. & Chen, J. Heterogeneity of tumor immune microenvironment in malignant and metastatic change in LUAD is revealed by single-cell RNA sequencing. Aging 15 (12), 5339\u20135354 (2023).","journal-title":"Aging"},{"key":"49053_CR27","doi-asserted-by":"publisher","first-page":"666396","DOI":"10.3389\/fgene.2021.666396","volume":"12","author":"S Jia","year":"2021","unstructured":"Jia, S. et al. Transcriptome Based Estrogen Related Genes Biomarkers for Diagnosis and Prognosis in Non-small Cell Lung Cancer. Front. Genet. 12, 666396 (2021).","journal-title":"Front. Genet."},{"key":"49053_CR28","first-page":"p6021602","volume":"2020","author":"W Meng","year":"2020","unstructured":"Meng, W. et al. FKBP4 Accelerates Malignant Progression of Non-Small-Cell Lung Cancer by Activating the Akt\/mTOR Signaling Pathway. Anal. Cell. Pathol. (Amsterdam). 2020, p6021602 (2020).","journal-title":"Anal. Cell. Pathol. (Amsterdam)"},{"key":"49053_CR29","doi-asserted-by":"publisher","first-page":"1015263","DOI":"10.3389\/fsurg.2022.1015263","volume":"9","author":"C Ma","year":"2022","unstructured":"Ma, C. et al. A more novel and powerful prognostic gene signature of lung adenocarcinoma determined from the immune cell infiltration landscape. Front. Surg. 9, 1015263 (2022).","journal-title":"Front. Surg."},{"issue":"5","key":"49053_CR30","first-page":"419","volume":"40","author":"M Yousefi","year":"2017","unstructured":"Yousefi, M. et al. Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options. Cell. Oncol. (Dordrecht Netherlands). 40 (5), 419\u2013441 (2017).","journal-title":"Cell. Oncol. (Dordrecht Netherlands)"},{"key":"49053_CR31","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.2147\/COPD.S380732","volume":"17","author":"C Qi","year":"2022","unstructured":"Qi, C., Sun, S. W. & Xiong, X. Z. From COPD to lung cancer: Mechanisms linking, diagnosis, treatment, and prognosis. Int. J. Chronic Obstr. Pulm. Dis. 17, 2603\u20132621 (2022).","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"1","key":"49053_CR32","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12943-017-0700-1","volume":"16","author":"S Yang","year":"2017","unstructured":"Yang, S. et al. FOXP3 promotes tumor growth and metastasis by activating Wnt\/\u03b2-catenin signaling pathway and EMT in non-small cell lung cancer. Mol. Cancer. 16 (1), 124 (2017).","journal-title":"Mol. Cancer"},{"key":"49053_CR33","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3389\/fonc.2019.01044","volume":"9","author":"X Zhu","year":"2019","unstructured":"Zhu, X. et al. EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies. Front. Oncol. 9, 1044 (2019).","journal-title":"Front. Oncol."},{"issue":"1","key":"49053_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.21037\/tlcr-22-507","volume":"12","author":"J Vad-Nielsen","year":"2023","unstructured":"Vad-Nielsen, J. et al. Genome-wide epigenetic and mRNA-expression profiling followed by CRISPR\/Cas9-mediated gene-disruptions corroborate the MIR141\/MIR200C-ZEB1\/ZEB2-FGFR1 axis in acquired EMT-associated EGFR TKI-resistance in NSCLC cells. Transl. Lung Cancer Res. 12(1), 42\u201365 (2023).","journal-title":"Transl. Lung Cancer Res."},{"issue":"8","key":"49053_CR35","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrc2887","volume":"10","author":"J Trepel","year":"2010","unstructured":"Trepel, J. et al. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer. 10 (8), 537\u2013549 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"49053_CR36","first-page":"p6021602","volume":"2020","author":"W Meng","year":"2020","unstructured":"Meng, W. et al. FKBP4 Accelerates Malignant Progression of Non-Small-Cell Lung Cancer by Activating the Akt\/mTOR Signaling Pathway. Anal. Cell. Pathol. (Amst). 2020, p6021602 (2020).","journal-title":"Anal. Cell. Pathol. (Amst)"},{"issue":"3","key":"49053_CR37","doi-asserted-by":"publisher","first-page":"e6938","DOI":"10.1002\/cam4.6938","volume":"13","author":"C Song","year":"2024","unstructured":"Song, C. et al. UCP2 promotes NSCLC proliferation and glycolysis via the mTOR\/HIF-1\u03b1 signaling. Cancer Med. 13 (3), e6938 (2024).","journal-title":"Cancer Med."},{"issue":"1","key":"49053_CR38","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12951-021-01085-y","volume":"19","author":"W Zhang","year":"2021","unstructured":"Zhang, W. et al. Tumor microenvironment-activated cancer cell membrane-liposome hybrid nanoparticle-mediated synergistic metabolic therapy and chemotherapy for non-small cell lung cancer. J. Nanobiotechnol. 19 (1), 339 (2021).","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"49053_CR39","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s13046-024-03202-9","volume":"43","author":"Y Zheng","year":"2024","unstructured":"Zheng, Y. et al. Mechanisms of neural infiltration-mediated tumor metabolic reprogramming impacting immunotherapy efficacy in non-small cell lung cancer. J. Experimental Clin. Cancer Research: CR. 43 (1), 284 (2024).","journal-title":"J. Experimental Clin. Cancer Research: CR"},{"issue":"18","key":"49053_CR40","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.7150\/jca.21035","volume":"8","author":"M Ye","year":"2017","unstructured":"Ye, M. et al. Combined inhibitions of glycolysis and AKT\/autophagy can overcome resistance to EGFR-targeted therapy of lung cancer. J. Cancer 8(18), 3774\u20133784 (2017).","journal-title":"J. Cancer"},{"issue":"1","key":"49053_CR41","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41392-024-01928-8","volume":"9","author":"T Zhang","year":"2024","unstructured":"Zhang, T. et al. Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation. Signal. Transduct. Target. Therapy. 9 (1), 216 (2024).","journal-title":"Signal. Transduct. Target. Therapy"},{"key":"49053_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13050941","author":"SE Dyrstad","year":"2021","unstructured":"Dyrstad, S. E. et al. Blocking aerobic glycolysis by targeting pyruvate dehydrogenase kinase in combination with EGFR TKI and ionizing radiation increases therapeutic effect in non-small cell lung cancer cells.. Cancers 13(5), 941 https:\/\/doi.org\/10.3390\/cancers13050941 (2021).","journal-title":"Cancers"},{"issue":"3","key":"49053_CR43","doi-asserted-by":"publisher","first-page":"188903","DOI":"10.1016\/j.bbcan.2023.188903","volume":"1878","author":"G Saha","year":"2023","unstructured":"Saha, G. et al. USP7 - a crucial regulator of cancer hallmarks. Biochim. Et Biophys. Acta Reviews Cancer. 1878 (3), 188903 (2023).","journal-title":"Biochim. Et Biophys. Acta Reviews Cancer"},{"key":"49053_CR44","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3389\/fcell.2020.00717","volume":"8","author":"GJ Valles","year":"2020","unstructured":"Valles, G. J. et al. USP7 Is a Master Regulator of Genome Stability. Front. Cell. Dev. Biology. 8, 717 (2020).","journal-title":"Front. Cell. Dev. Biology"},{"issue":"20","key":"49053_CR45","doi-asserted-by":"publisher","first-page":"9332","DOI":"10.7150\/thno.47137","volume":"10","author":"X Dai","year":"2020","unstructured":"Dai, X. et al. USP7 targeting modulates anti-tumor immune response by reprogramming tumor-associated macrophages in Lung Cancer. Theranostics 10(20), 9332\u20139347 (2020).","journal-title":"Theranostics"},{"issue":"7","key":"49053_CR46","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41418-023-01180-7","volume":"30","author":"J Yi","year":"2023","unstructured":"Yi, J. et al. Inhibition of USP7 induces p53-independent tumor growth suppression in triple-negative breast cancers by destabilizing FOXM1. Cell Death Differ. 30 (7), 1799\u20131810 (2023).","journal-title":"Cell Death Differ."},{"issue":"11","key":"49053_CR47","doi-asserted-by":"publisher","first-page":"114917","DOI":"10.1016\/j.celrep.2024.114917","volume":"43","author":"B Huang","year":"2024","unstructured":"Huang, B. et al. USP7 deubiquitinates KRAS and promotes non-small cell lung cancer. Cell. Rep. 43 (11), 114917 (2024).","journal-title":"Cell. Rep."},{"issue":"7677","key":"49053_CR48","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature24451","volume":"550","author":"AP Turnbull","year":"2017","unstructured":"Turnbull, A. P. et al. Molecular basis of USP7 inhibition by selective small-molecule inhibitors. Nature 550 (7677), 481\u2013486 (2017).","journal-title":"Nature"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49053-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49053-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49053-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T01:15:52Z","timestamp":1781745352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49053-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["49053"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-49053-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Medical Ethics Committee of Guangzhou Red Cross Hospital (approval No. Red-Med-Ethics-2025-177-01). Written informed consent was obtained from all participants, and all procedures were conducted in accordance with the Declaration of Helsinki and relevant national regulations. Animal experiments were reviewed and approved by the Animal Welfare and Ethics Committee of Guangzhou Red Cross Hospital (approval No. Red-Animal-Ethics-2025-014-01; production license No. SCXK(Yue)2021-0041). All animal work complied with relevant national regulations and the ARRIVE guidelines, and every effort was made to minimize animal suffering.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"18984"}}